ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
13.99
-0.47 (-3.25%)
At close: Aug 27, 2026, 4:00 PM EDT
14.27
+0.28 (2.00%)
After-hours: Aug 27, 2026, 7:54 PM EDT
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
125.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| LENZ Therapeutics | 21.48M |
| Equillium | 4.39M |
| Cibus | 4.35M |
| Inovio Pharmaceuticals | 65.34K |
PMN News
- 6 days ago - ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital - TheFly
- 11 days ago - ProMIS Neurosciences reports Q2 EPS ($1.28), consensus ($1.90) - TheFly
- 11 days ago - ProMIS Neurosciences price target raised to $100 from $69 at Guggenheim - TheFly
- 14 days ago - ProMIS Neurosciences Earnings Call Transcript: Q2 2026 - Transcripts
- 14 days ago - ProMIS Neurosciences Quarterly report: Q2 2026 - Filings
- 14 days ago - ProMIS Neurosciences Earnings release: Q2 2026 - Filings
- 14 days ago - ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 24 days ago - ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - GlobeNewsWire